Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
In this application note, we demonstrate how the C
The Nobel Prize in Physiology or Medicine awarded
In today’s rapidly evolving bioprocessing landsc
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Mi
Drug maker Wockhardt on Friday said it has inked a pact with Dubai-based Enso Healthcare and a subsidiary of Russian Direct Investment Fund (RDIF) for production and supply of COVID-19 vaccine Sputnik.
The Mumbai-based firm has entered into an agreement with Enso and Human Vaccine LLC , a wholly owned unit of the management company of RDIF to manufacture and supply Sputnik V, Sputnik Light vaccine against COVID-19, Wockhardt said in a regulatory filing.
Subject to requisite approvals and other conditions, upon successful technology transfer from Human Vaccine LLC, the company will manufacture and supply to Enso up to 620 million doses of the Sputnik V and the Sputnik Light vaccines, it added.
“The term of the agreement is up to June 2023 for the contract manufacturing of up to 620 million doses of Sputnik V and Sputnik Light,” Wockhardt noted.
